Insider Selling: Cerus Co. (CERS) CEO Sells 7,781 Shares of Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 7,781 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $6.48, for a total value of $50,420.88. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of CERS stock traded down $0.12 during mid-day trading on Thursday, reaching $6.16. The stock had a trading volume of 42,696 shares, compared to its average volume of 842,462. The stock has a market capitalization of $877.87 million, a price-to-earnings ratio of -14.02 and a beta of 1.44. The company has a current ratio of 2.79, a quick ratio of 2.53 and a debt-to-equity ratio of 0.26. Cerus Co. has a 52-week low of $4.70 and a 52-week high of $8.05.

Cerus (NASDAQ:CERS) last announced its earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $16.50 million for the quarter, compared to the consensus estimate of $18.74 million. Cerus had a negative net margin of 84.15% and a negative return on equity of 65.35%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.10) EPS. Equities analysts predict that Cerus Co. will post -0.42 EPS for the current year.

CERS has been the subject of a number of analyst reports. BidaskClub upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research upgraded shares of Cerus from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Monday, February 4th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price objective on shares of Cerus in a research report on Monday, December 10th. Finally, ValuEngine upgraded shares of Cerus from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Cerus presently has a consensus rating of “Buy” and a consensus price target of $8.50.

Several institutional investors and hedge funds have recently made changes to their positions in CERS. Two Sigma Securities LLC bought a new stake in shares of Cerus during the 4th quarter valued at about $55,000. Raymond James Trust N.A. bought a new stake in shares of Cerus during the 4th quarter valued at about $71,000. Shufro Rose & Co. LLC boosted its stake in shares of Cerus by 13.3% during the 4th quarter. Shufro Rose & Co. LLC now owns 17,000 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 2,000 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Cerus by 141.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 19,824 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 11,624 shares in the last quarter. Finally, Amalgamated Bank bought a new stake in shares of Cerus during the 4th quarter valued at about $99,000. 65.15% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Insider Selling: Cerus Co. (CERS) CEO Sells 7,781 Shares of Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2019/03/14/insider-selling-cerus-co-cers-ceo-sells-7781-shares-of-stock.html.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Story: What is the QQQ ETF?

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit